Page last updated: 2024-11-06

idremcinal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Idremcinal: a motilin receptor agonist in human gastric antrum; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID84019
CHEMBL ID2103968
SCHEMBL ID21931814
MeSH IDM0238165

Synonyms (27)

Synonym
idremcinal
idremcinal (usan/inn)
110480-13-2
D04497
(2r,3r,4s,5r,8r,9s,10s,11r,12r)-5-ethyl-3,4-dihydroxy-9-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2s,3r,4s,6r)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec
8,9-didehydro-n-demethyl-9-deoxo-6-deoxy-6,9-epoxy-n-isopropylerythromycin
unii-0m6189xxjn
em574
em-574
8,9-didehydro-n-demethyl-9-deoxo-6-deoxy-6,9-epoxy-n-(1-methylethyl)erthromycin
idremcinal [usan:inn]
8,9-didehydro-n-demethyl-9-deoxo-6-deoxy-6,9-epoxy-n-(1-methylethyl)erythromycin
0m6189xxjn ,
CHEMBL2103968
AKOS025294079
idremcinal [usan]
idremcinal [inn]
HB3887
em 574
J-002432
DTXSID10891360
SCHEMBL21931814
(2r,3r,4s,5r,8r,9s,10s,11r,12r)-5-ethyl-3,4-dihydroxy-11-(((2s,3r,4s,6r)-3-hydroxy-4-(isopropyl(methyl)amino)-6-methyltetrahydro-2h-pyran-2-yl)oxy)-9-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-2,4,8,10,12,14-hexamethyl-6
gtpl11813
Q27236956
HY-105263
CS-0025533

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Thirty healthy volunteers received one of five oral doses of EM574 (5, 10, 20, 30 mg and placebo) in a randomized, double-blind, five-period, cross-over design; each dosing period was separated by 1-wk washout."( Dose-related effects of N-demethyl-N-isopropyl-8, 9-anhydroerythromycin A 6,9-hemiacetal on gastric emptying of solids in healthy human volunteers.
Burton, DD; Camilleri, M; Choi, MG; Edmonds, A; Johnson, S, 1998
)
0.3
" The cumulative amount (A(app)) of drug appearing in the systemic circulation was calculated by deconvolution, where the input response was the plasma concentration-time profile during intestinal perfusion and the unit impulse response was the mean profile following intravenous bolus dosing to sham-operated rabbits in a separate experiment."( Intestinal absorption and presystemic elimination of the prokinetic agent, EM574, in the rabbit.
Cartier, LL; Gan, G; Huang, Y; Sawchuk, RJ; Yang, Z, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (64.71)18.2507
2000's6 (35.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.24 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.56%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]